BCL2 and acute myeloid leukemia: A separate study found that venetoclax, a BCL-2 inhibitor, synergizes with tedizolid, an inhibitor of mitochondrial protein synthesis, to activate the ISR causing cell death through an inhibition of glycolytic activity in venetoclax-resistant AML (152).